Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CD274 | Q9NZQ7 | 12/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | BCHE | P06276 | 2/20 | 0.46 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.45 |
| ▸ | MAOB | P27338 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | ALOX12 | P18054 | 2/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4599002 | 0.75 | MAOB (0.54) | ALDH1A1RAB9AMAOBMAPTALOX12 | |
| SCHEMBL13114964 | 0.74 | PTPN1 (0.53) | CD274ALDH1A1KDM4EBCHEPTPN1 | |
| SCHEMBL6701157 | 0.74 | MAOB (0.61) | ALDH1A1BCHEMAOBMAPTALOX12 | |
| SCHEMBL1745424 | 0.74 | MAOB (0.53) | NPC1RAB9ABCHEMAOBMAPT | |
| Dimethylamine SCHEMBL25239231 | 0.73 | MAOB (0.49) | CD274ALDH1A1BCHEPTPN1MAOB | |
| SCHEMBL21275467 | 0.73 | ERN1 (0.49) | CD274PTPN1MAOBL3MBTL1 | |
| SCHEMBL27998563 | 0.73 | MAOB (0.59) | ALDH1A1BCHEMAOBGAASMN1; SMN2 | |
| SCHEMBL31643956 | 0.72 | ERN1 (0.48) | NPC1RAB9APTPN1MAOBMAPT | |
| SCHEMBL1554192 | 0.71 | MAOB (0.54) | KDM4ENPC1RAB9ABCHEMAOB | |
| SCHEMBL25282560 | 0.71 | MAOB (0.57) | ALDH1A1BCHEMAOBMAPTALOX12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1556034-B1 | INDOLE DERIVATIVES AS BETA-2 AGONISTS | PFIZER LTD (GB) | 2008-04-16 | — | — | EP | disclosed |
| EP-1556034-B1 | INDOLE DERIVATIVES AS BETA-2 AGONISTS | PFIZER LTD (GB) | 2008-04-16 | — | — | EP | disclosed |
| US-7138527-B2 | Inflammatory, allergic and respiratory disorders; beta 2 adrenoceptors agonists; such as 5-(-2-((-2-hydroxy-2-(4-hydroxy-3-(hydroxymethyl)phenyl)ethyl)amino)propyl) -N-(2-methoxybenzyl)-1H-indole-2-carboxamide | PFIZER INC. (US) | 2006-11-21 | — | — | US | disclosed |
| EP-1556034-A1 | INDOLE DERIVATIVES AS BETA-2 AGONISTS | Pfizer Limited (GB) | 2005-07-27 | — | — | EP | disclosed |
| US-20050085526-A1 | Indole derivatives useful for the treatment of diseases | BROWN ALAN D (GB) | 2005-04-21 | — | — | US | disclosed |
| US-6844362-B2 | Indole derivatives useful for the treatment of diseases | PFIZER INC (US) | 2005-01-18 | — | — | US | disclosed |
| EP-1440966-A1 | Indole derivatives useful for the treatment of diseases | Pfizer Limited (GB) | 2004-07-28 | — | — | EP | disclosed |
| US-20040116503-A1 | Indole derivatives useful for the treatment of diseases | PFIZER INC. | 2004-06-17 | — | — | US | disclosed |
| WO-2004032921-A1 | INDOLE DERIVATIVES AS BETA-2 AGONISTS | PFIZER LIMITED (GB) | 2004-04-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050085526-A1 | Indole derivatives useful for the treatment of diseases | IDO1, IDO2, INMT | CD274 3743/4885ALDH1A1 549/4885KDM4E 2028/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.